SAN ANTONIOBevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), conferred additional benefit to paclitaxel(Drug information on paclitaxel) when the combination was used as first-line therapy in locally recurrent and metastatic breast cancer patients in the Eastern Cooperative Oncology Group (ECOG) phase III E2100 study. Kathy D. Miller, MD, of Indiana University Cancer Center, Indianapolis, reported the updated results at the 28th Annual San Antonio Breast Cancer Symposium (abstract 3). "This is a positive study," Dr. Miller said. "The addition of bevacizumab(Drug information on bevacizumab) to paclitaxel more than doubled the response rate and significantly prolonged progression-free survival."Tumor growth is dependent upon angiogenesis, and bevacizumab recognizes all VEGF-A isoforms. It has shown activity in patients with highly refractory metastatic breast cancer, yielding a 9% response rate as monotherapy, Dr. Miller noted. "Since proangiogenic factors become more numerous as breast cancers progress, we expect greater activity of this agent in patients with less heavily pretreated disease," she said. "E2100 was designed to test this hypothesis."
E2100 randomized 722 breast cancer patients with locally recurrent or metastatic disease to paclitaxel alone (90 mg/m2 on days 1, 8, and 15 every 4 weeks), or the same paclitaxel regimen plus bevacizumab 10 mg/kg on days 1 and 15.
Interim analyses were planned after 270 and 425 progression-free survival events, with the final analysis to occur after 546 events. The current data cut-off occurred September 27, 2005, after 484 events, including 426 cases of disease progression and 58 deaths without documented progression.
Patients receiving the combination of paclitaxel plus bevacizumab demonstrated significant improvements in overall response rate and progression-free survival, Dr. Miller reported."The addition of bevacizumab more than doubled the objective response rate, from 13.8% to 29.9%. These results were highly significant (P < .0001)," she said. She noted that the response rates are in keeping with patients who have had significant exposure to prior chemotherapy, adding that "the response rates in E2100 are actually ‘artificially low' because we included patients who did not have measurable disease. By definition, these patients' responses could only have been progressive disease, complete response, or stable disease; partial response was not an available category for these patients." The evaluation of only patients with measurable disease at entry showed similar results to that of the overall population.
The improvement in response rate translated into a dramatic improvement in progression-free survival (11.4 months for the combination vs 6.11 months for paclitaxel alone, P < .0001). "The curves separated early and remained widely separate throughout the follow-up," she noted. "With a hazard ratio of 0.51, these results are both highly statistically and clinically meaningful."